Rapid Micro Biosystems (NASDAQ:RPID) Stock Rating Cut to Neutral at Roth Capital

Rapid Micro Biosystems (NASDAQ:RPID – Get Free Report) was downgraded by equities research analysts at Roth Capital from a “buy” rating to a “neutral” rating in a research note issued to investors on Tuesday, FinViz reports. They presently have a $0.75 price objective on the stock, down from their previous price objective of $3.00. Roth Capital‘s price target would suggest a potential upside of 1.35% from the stock’s previous close.

A number of other analysts have also issued reports on RPID. Weiss Ratings reissued a “sell (d-)” rating on shares of Rapid Micro Biosystems in a research report on Thursday, October 15th. JPMorgan Chase & Co. set a $0.75 price target on shares of Rapid Micro Biosystems in a report on Tuesday. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $1.81.

Check Out Our Latest Stock Analysis on RPID

Rapid Micro Biosystems Stock Up 13.7%

NASDAQ:RPID opened at $0.74 on Tuesday. The firm has a market capitalization of $37.12 million, a price-to-earnings ratio of -0.66 and a beta of 1.52. Rapid Micro Biosystems has a 1-year low of $0.58 and a 1-year high of $4.94. The company has a current ratio of 2.55, a quick ratio of 1.51 and a debt-to-equity ratio of 1.08. The business’s fifty day moving average price is $0.91 and its 200 day moving average price is $2.06.

Rapid Micro Biosystems (NASDAQ:RPID – Get Free Report) last announced its quarterly earnings data on Monday, November 16th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.01). Rapid Micro Biosystems had a negative return on equity of 177.04% and a negative net margin of 145.56%. The business had revenue of $9.53 million during the quarter, compared to analysts’ expectations of $9.85 million. On average, sell-side analysts forecast that Rapid Micro Biosystems will post -0.94 earnings per share for the current fiscal year.

Institutional Trading of Rapid Micro Biosystems

A number of institutional investors have recently bought and sold shares of RPID. Pekin Hardy Strauss Inc. purchased a new stake in shares of Rapid Micro Biosystems during the 3rd quarter worth about $41,000. Bank of America Corp DE grew its stake in shares of Rapid Micro Biosystems by 139.9% in the 1st quarter. Bank of America Corp DE now owns 31,014 shares of the company’s stock valued at $70,000 after buying an additional 18,085 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of Rapid Micro Biosystems by 9.5% in the 1st quarter. Renaissance Technologies LLC now owns 126,617 shares of the company’s stock valued at $287,000 after buying an additional 10,990 shares in the last quarter. Sei Investments Co. increased its holdings in Rapid Micro Biosystems by 204.2% in the first quarter. Sei Investments Co. now owns 284,816 shares of the company’s stock worth $647,000 after buying an additional 191,200 shares during the last quarter. Finally, Temasek Holdings Private Ltd acquired a new position in Rapid Micro Biosystems in the first quarter worth approximately $50,000. Institutional investors and hedge funds own 52.60% of the company’s stock.

Rapid Micro Biosystems News Summary

These are some of the RPID news items that stood out recently:

  • Positive Sentiment: Merck KGaA signed a definitive agreement to acquire all outstanding RPID shares for $0.75 each in cash. Merck said Rapid Micro’s Growth Direct platform would strengthen its pharmaceutical quality-control workflow offerings. Acquisition announcement
  • Neutral Sentiment: Law firms announced investigations into whether the $0.75 offer fairly values RPID and whether deal terms could limit competing offers. These are inquiries, not findings, but could add uncertainty around the transaction. Shareholder investigation report
  • Negative Sentiment: Third-quarter results were slightly below analyst expectations: RPID reported a $0.22-per-share loss versus estimates of $0.21, and revenue of $9.53 million versus estimates of $9.85 million. The company also filed a notification of late quarterly filing, adding a reporting concern. Third-quarter results Late filing report

Rapid Micro Biosystems Company Profile

(Get Free Report)

Rapid Micro Biosystems develops automated microbial detection systems for pharmaceutical, biotechnology and other life sciences manufacturers. Its products are designed to support quality-control testing by identifying and measuring microbial growth in manufacturing environments and products. The company’s Growth Direct platform combines laboratory instruments, consumables and software to automate microbial testing. Its applications include sterility testing, bioburden testing and environmental monitoring, helping manufacturers assess contamination during production.

Read More

Receive News & Ratings for Rapid Micro Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapid Micro Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.